hotspot -WSS

hotspot

author：comprehensive 2025-08-28 06:16:58 - browse：8

3d rendered medically accurate illustration of the adrenal gland – biotech and pharma coverage from STAT — Adobe

SAN DIEGO — Neurocrine Biosciences announced on Tuesday that an experimental drug for congenital adrenal hyperplasia succeeded in a late-stage trial, bringing the company a step closer to treating patients with a rare and serious set of genetic disorders that alters their ability to produce key hormones.

In the Phase 3 study, known as CAHtalyst, 182 adults were randomly assigned to receive a placebo or crinecerfont, an oral drug Neurocrine developed to lower male sex hormones patients with the disease produce in excess. Researchers found that, compared to those on placebo, participants who took crinecerfont needed a significantly lower dose of the current standard-of-care treatment, glucocorticoids, after 24 weeks of treatment that they did at the study’s start. And about 63% of participants who took crinecerfont were able to lower their dose of glucocorticoids to levels researchers think would be safer for prolonged use, compared to 18% of those on the placebo.

Neurocine, a San Diego biotech focused on treating rare neurological and endocrine diseases, believes the drug could allow people living with congenital adrenal hyperplasia, or CAH, to avoid some of the more serious side effects of glucocorticoids by allowing them to take lower doses. Long-term use of high doses of these drugs can cause patients to gain weight and put them at risk of diabetes, heart disease, and osteoporosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： High breast density mammograms need follow

WSS

There's an unseen cost to disruptive road

A pediatrician calls for Congress to pass the child tax credit deal

HPV vaccine, cervical cancer study delivers historic results

US ambassador visits Wall Street Journal reporter detained in Russia on charges of espionage

FDA endorses new sterilization method for medical devices

Palestinian attacker wounds 8 in Tel Aviv as Israel presses on with West Bank operation

hotspot

hotspot

hotspot

Hepatitis C has a cure — but many Americans still lack access to it

US judge blocks portions of new Florida elections law

Novavax promises a turnaround & Lilly roils the obesity market

Medicare drug price lawsuits could be good politics for Biden

Virginia high school admissions case could be legal follow

US recommends Americans reconsider traveling to China due to arbitrary law enforcement, exit bans

Hepatitis C has a cure — but many Americans still lack access to it

ThunderShirts, dance parties and anxiety meds can help ease dogs' July Fourth dread

Alkermes shareholders re

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

focus

Russians and Belarusians back at Wimbledon as war in Ukraine continues

High breast density mammograms need follow

Leon Gautier, last member of French D

EU climate chief is concerned over the expansion of the coal industry in China

What causes osteoarthritis? Researchers study link to brain protein

Trump pressured former Arizona governor to overturn 2020 election results: Sources

hotspot

hotspot

leisure time

entertainment